BioSpace News Archive

LimFlow SA announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the LimFlow Percutaneous Deep Vein Arterialization System.

First multi-site randomized trial shows stellate ganglion block is effective in treating PTSD symptoms in active-duty service members

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019

Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meeting on the health economics of norovirus disease on Thursday, November 14th in New York City.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources, effectively immediately.

MannKind Corporation (NASDAQ:MNKD) today reported preliminary financial results for the quarter and nine months ended September 30, 2019.

Primmune Therapeutics announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small molecule toll-like receptor 7 agonist that activates innate immunity by systemically targeting plasmic cytoid dendritic cells in vivo.

Presentation of 87 Abstracts Revealing New Insights into Acute Kidney Injury, Artificial Intelligence Technology, Home Dialysis, and Other Efforts to Improve Patient Outcomes

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced that the Company’s management will present its platform technology and discuss potential utility of RNAi therapeutics at two conferences in November 2019.

Vyaire Medical, Inc.'s bellavista 1000e ventilator has been granted 510 clearance from the U.S. Food and Drug Administration It is the newest addition to Vyaire’s high-end ventilation portfolio offering a comprehensive solution for hospitals with the integration of high flow oxygen therapy and advanced synchrony support for neonatal to adult patients in a single device.